Want to buy for someone else? You can purchase a token at check out.

Overview
Goals and Outcomes
Details
Accreditations
Overview
Overview

This course prepares the healthcare professional with a basic overview of cannabis as medicine. Contents include a brief history of cannabis use and prohibition,safety-ethical-legal concerns, the human endocannabinoid system, an overview of the cannabis plant components, and cannabis as an evidence-based medicine. Learners will explore ways cannabis can be ingested, dosing approaches, side effects, and medication interactions. Implications for various healthcare professions are explored, and professional guidelines, ethics, and advocacy are highlighted

This program has been approved for 1.0 hours by The Commission for Case Manager Certification from 02/14/2020 to 02/14/2021.

Goals and Outcomes
Goals and Learning Outcomes
This course has been approved for 1 hour by the Commission on Case Manager Certification for 2/14/2019 to 2/14/2020.

The goal of this course is to prepare members of the interprofessional team with a basic overview of cannabis as medicine including a brief history of cannabis use and prohibition, safety-ethical-legal concerns, the human endocannabinoid system, an overview of the cannabis plant components, and cannabis as an evidence-based medicine. Upon completion, participants will be able to do the following:

  • Review the history of cannabis prohibition.
  • Briefly discuss the endocannabinoid system and how holistic-integrative modalities support endocannabinoid system health.
  • Discuss functional aspects of utilizing cannabis as a therapeutic modality including the entourage effect of its components, ingestion methods, dosing, and recreational vs medicinal use of cannabis including pertinent medication interactions, side effects and other safety issues.
  • Examine the available evidence around effectiveness of medicinal cannabis for specific disease issues.
  • Review legal-ethical issues related to specific state laws and state practice acts related to cannabis and how these issues impact the interprofessional team.
Details
Course Details

Course Originally Released on : 8/30/2018

WEB361

Course Author

Carey S. Clark

PhD, RN, AHN-BC, RYT, FAAN

Accreditations
Accreditations

NURSES
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Accreditations imageAccreditations image

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

CEBroker
Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Examiners For Registered Professional Nurses
Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

Disclosures
None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.